A Phase 1 interventional study of ELVN-001 in CML (Chronic Myelogenous Leukemia) and Chronic Phase CML, sponsored by Enliven Therapeutics. Recruiting at 4 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Enliven Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan — 5 open to participants now, 7 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan.
Among the 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan, this one is the 26th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 31st registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →5 of the 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, United States, Australia and 14 more countries
Ages 1–18
Ascentage Pharma Group Inc. · Sites in Japan, United States, Australia and 13 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, United States, Argentina and 26 more countries
Ages 7–100
Poitiers University Hospital · Sites in Japan, Australia, Austria and 17 more countries
Ages up to 18
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 16 · Phase 3 7 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 59 across the 29 interventional studies, 550 across the 3 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 32 have an industry lead sponsor. The 10 most frequent:
Enliven Therapeutics is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Enliven Therapeutics has 3 studies filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
2 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.
This first-in-human trial with ELVN-001 is a dose escalation study with the primary purpose to identify the recommended dose(s) for expansion (RDEs) of single agent ELVN-001 in chronic phase CML with or without T315I mutations. The safety, tolerability and pharmacokinetic profile of ELVN-001 will be assessed together with an evaluation of changes in BCR-ABL1 transcript. An understanding of the safety profile, PK and preliminary evidence of anti-CML activity will be used to inform future development of ELVN-001 in adults with CML. By virtue of its predicted pharmacological profile ELVN-001 has the potential to be tolerable and achieve a deep molecular response in patients with CML with or without T315I mutations who have failed, or are intolerant to, or not a candidate for, at least 2 prior TKIs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ELVN-001 administered in 3+3 dose escalation
Drug: ELVN-001
ELVN-001 administered to approximately 6 participants per dose level who may be enrolled at or below the dose levels that have been deemed safe and tolerable in Part 1
Drug: ELVN-001
Orally once or twice daily
Part 1: Incidence of dose limiting toxicities
DLTs will be used to support that the recommended doses for expansion are \</= MTD
Time frame: 28 days
Part 1: Incidence of adverse events (AEs)
Adverse events will be used to support that the recommended doses for expansion are likely to be tolerable
Time frame: Up to 28 days
Part 1: Incidence of clinically significant laboratory abnormalities
Clinically significant laboratory abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable
Time frame: Up to 28 days
Part 1: Incidence of clinically significant ECG abnormalities
Clinically significant ECG abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable
Time frame: Up to 28 days
Part 2: Incidence of adverse events
Adverse events will be used to support that the dose(s) evaluated in exploration is tolerable
Time frame: Up to 3 years
Part 2: Incidence of clinically significant laboratory abnormalities
Clinically significant ECG abnormalities will be used to support that the dose(s) evaluated in exploration is tolerable
Time frame: Up to 3 years
Part 2: Incidence of clinically significant ECG abnormalities
Clinically significant ECG abnormalities will be used to support that the recommended dose(s) evaluated in exploration is tolerable
Time frame: Up to 3 years
Area under the curve
PK parameter based on measurement of drug concentration in blood over time
Time frame: 6 months
Maximum concentration
PK parameter based on measurement of drug concentration in blood
Time frame: 6 months
Time of maximum concentration
PK parameter which is the time at which the highest concentration of drug in the blood is measured
Time frame: 6 months
Minimum concentration
PK parameter based on the measurement of the drug concentration that is at the lowest level once steady state has been achieved.
Time frame: 6 months
Molecular response (MR)
Measured by quantitative polymerase chain reaction of BCR-ABL transcript levels
Time frame: Up to 3 years
Duration of Molecular Response
Time from first molecular response (as measured by quantitative polymerase chain reaction of BCR-ABL transcript levels) to loss of response or discontinuation of study drug
Time frame: Up to 3 years
Complete Hematologic Response (CHR)
The proportion of patients who achieve a CHR who are not in CHR at baseline
Time frame: Up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 36 months after the start.
Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relcobatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →
Enliven Therapeutics